KPV
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), representing the minimal sequence required for much of α-MSH's anti-inflammatory activity. Unlike full α-MSH, KPV does not significantly activate melanocortin receptors in the traditional sense; its anti-inflammatory effects appear to operate through direct NF-κB inhibition and modulation of intestinal epithelial barrier function. Preclinical evidence in colitis models is consistent — oral and intracolonic administration reduces inflammatory markers and mucosal damage in rodent IBD models. No human clinical trials have been published; KPV remains a research compound without established dosing, safety profile, or regulatory status in any jurisdiction.
Evidence last reviewed: 04 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
Preclinical studies suggest KPV may reduce inflammation and mucosal damage in colitis models, but the evidence is limited and primarily animal-based. There are no human trials, which raises questions about its efficacy and safety in people.
Colitis-associated cancer prevention (preclinical)Mouse models (PepT1-expressing) · Preclinical (animal)Low
KPV transported via PepT1 reduced colitis severity & prevented carcinogenesis in murine colitis-associated cancer models; no human trials identified.
Colitis severity reductionMouse colitis models + cellular models · Preclinical (cell + mouse)Low
KPV showed anti-inflammatory effects mediated by PepT1 transport in intestinal epithelial/immune cells & reduced inflammation in mouse colitis models.
Targeted KPV delivery for ulcerative colitis (preclinical)Mouse ulcerative colitis models (DSS and TNBS) · Preclinical (animal + in vitro)Low
Hyaluronic acid-functionalized nanoparticles loaded with KPV showed targeted delivery to colonic epithelial cells & macrophages, reducing inflammation in murine UC models; translational relevance to humans is not established.
Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).
KLOW Stack
The KLOW stack is a 4-peptide protocol targeting systemic inflammation, tissue repair, and cellular regeneration. It combines BPC-157 (gut and musculoskeletal healing), TB-500 (vascularisation and muscle/tendon recovery), KPV (anti-inflammatory gut protection), and GHK-Cu (collagen remodelling and skin/hair health). It is designed as an evolution of the GLOW stack with a stronger anti-inflammatory focus and broader systemic repair coverage.